Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

10/31/16 PR
"Cellceutix anticipates conducting an interim analysis of 6-week data from this Phase 2b trial in chronic plaque psoriasis with readout available in 2Q2017 and full study top-line results in 3Q2017."

12/19/16 PR:
Interim results are anticipated to be available in 3Q2017.

Posted on 9/14/17:
"From Leo:
Our plan was to to do an interim analysis of patients who completed week 6 and look for a signal. Recruitment into the study was slower than anticipated. At this time, as most patients have completed the study, a look could create investigator bias. It will likely effect the Alpha and require more patients to be added to the study.

I do appreciate your suggestions but it is very complicated.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134607215


October 31, 2017
Innovation Pharmaceuticals Phase 2b Psoriasis Study On-Track for Completion in December 2017;
(Interim results not mentioned)

December 21, 2017
Innovation Pharmaceuticals Completes Final Patient Visit in Phase 2b Study of Oral Prurisol for Psoriasis


On December 14, 2018, the Company completed its review of preliminary topline results for its Phase 2b clinical trial of oral Prurisol in moderate-to-severe chronic plaque psoriasis. Data was received the previous week.

The investigational treatment Prurisol did not meet the primary endpoint in either treatment arm (300mg and 400mg) assessed as a measure of efficacy (active versus control) using the Psoriasis Area and Severity Index (PASI) scale—specifically, the proportion of subjects achieving at least a 75 percent reduction from baseline in PASI score (PASI75) at Week 12.

While additional analysis of the Prurisol data is planned, based on these trial results, the Company will discontinue the Prurisol psoriasis program, focusing development efforts on advancing its other clinical assets, Kevetrin and Brilacidin, both of which have shown therapeutic potential in treating multiple indications.